Proactive Investors - Run By Investors For Investors

Pressure BioSciences PCT platform could play pivotal role in improving cancer diagnosis

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive Investors that scientists from Australia’s Centre for the Proteome of Human Cancer (ProCan) have published a recommended proteomic sample preparation protocol built around its Barocycler instrument system, based around Pressure Bio’s proprietary pressure cycling technology (PCT) platform, which may help to identify and use new cancer biomarkers.

In addition to this, Schumacher has filed a Form 4 with the SEC, and Schumacher says he's purchased shares of stock to show good faith in the company. Schumacher will hold an investor conference call 4:30PM Wednesday.

 
View full PBIO profile View Profile

Pressure BioSciences Inc. Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use